ReviewEuropean heart journal. Cardiovascular pharmacotherapy2017
Plaque imaging to refine indications for emerging lipid-lowering drugs.
Review in European heart journal. Cardiovascular pharmacotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Colchicine in Patients with Coronary Artery Disease with or Without Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials.Clinical drug investigation · 2021Pooled it
- Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease.Journal of the American Heart Association · 2021Pooled it
- Assessment of Therapeutic Response to Statin Therapy in Patients With Intracranial or Extracranial Carotid Atherosclerosis by Vessel Wall MRI: A Systematic Review and Updated Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Statin therapy reduces vertebral artery atherosclerotic plaques: a case report with insight from vessel wall magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2025Article
- Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies.Journal of cardiovascular development and disease · 2024Review
- The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications.Journal of clinical medicine · 2023Review
- Advances in Cardiovascular Pharmacology in Atherosclerotic-Related Therapeutic Areas: Addressing Patients' Clinical Needs.Journal of clinical medicine · 2023Article
- Novel Applications for Invasive and Non-invasive Tools in the Era of Contemporary Percutaneous Coronary Revascularisation.Current cardiology reviews · 2022Review
- Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol.World journal of cardiology · 2021Review
- Micro Spectroscopic Photoacoustic (μsPA) imaging of advanced carotid atherosclerosis.Photoacoustics · 2021Article
- Imaging as a surrogate marker of drug efficacy in cardiovascular disease.Heart (British Cardiac Society) · 2019Article
- Current concepts in atherosclerosis.Indian journal of thoracic and cardiovascular surgery · 2018Article
- The relationship of perivascular adipose tissue and atherosclerosis in the aorta and carotid arteries, determined by magnetic resonance imaging.Diabetes & vascular disease research · 2018Article
- Quantification of carotid plaque lipid content with magnetic resonance T2 mapping in patients undergoing carotid endarterectomy.PloS one · 2017Article
- A promising tool to tackle the risk of cerebral vascular disease, the emergence of novel carotid wall imaging.Brain circulationReview
- Role ofWorld journal of nuclear medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Statins have been effective in reducing adverse cardiovascular events. Their benefits have been proportional to the level of plasma LDL-cholesterol reduction and seem to extend to patients with 'normal' levels of cholesterol at outset. Statins are also inexpensive and have a favourable side-effect profile. As a result, they are used widely (almost indiscriminately) in patients with atherosclerotic vascular disease, and in those at risk of disease. Next generation lipid-modifying drugs seem unlikely to offer the same simplicity of application. The recent trials of new classes of lipid modifying drugs underline the need for a risk stratification tool which is not based on patients' category of diagnosis (for example, post-myocardial infarction) but based on the characterization of disease in that individual patient. Mechanistic staging, a process that matches the target of the drug action with an identifiable disease characteristic, may offer an opportunity to achieve more precise intervention. The upshots of this targeted approach will be greater efficacy, requiring smaller clinical trials to demonstrate effectiveness; a reduced number needed to treat to yield benefits and more cost-effective prescribing. This will be important, as purchasers require ever more rigorous demonstration of both efficacy and cost-effectiveness. In this context, we will discuss available pharmacological strategies of lipid reduction in anti-atherosclerotic treatment and how plaque imaging techniques may provide an ideal method in stratifying patients for new lipid-modifying drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.